Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New hope for DMD: experimental drug opens to more patients
Disease control AVAILABLEThis program provides access to an investigational drug, AOC 1044, for people with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by skipping exon 44. It is for eligible patients aged 6 and older living in the US. The goal is to offer treatment while gath…
Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 11:57 UTC
-
New hope for FSHD: phase 3 trial of AOC 1020 begins
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 adults with a confirmed FSHD diagnosis who can still walk will receive either the drug or a placebo by I…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 11:56 UTC